The story of the erectile dysfunction drug presents a challenging picture for those considering investment. While the initial launch generated massive returns, the lapse of its patent opened the floodgates to off-brand https://bookmarkbooth.com/story21664283/the-copyright-and-the-pharmaceutical-industry-a-risky-opportunity